General Information of Drug (ID: DMVQG8G)

Drug Name
A336 Drug Info
Indication
Disease Entry ICD 11 Status REF
Clotting disorder 3B4Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMVQG8G

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Coagulation factor XI (F11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
A186 DMHJ0EB Clotting disorder 3B4Z IND submitted [1]
Asundexian DMLZMU2 Ischemic stroke 8B11.5Z Phase 3 [2]
Abelacimab DM09YTN Atrial fibrillation BC81.3 Phase 2 [3]
MK-2060 DM79A32 Thrombosis DB61-GB90 Phase 2 [4]
EP-7041 DMV0MHI Thrombosis DB61-GB90 Phase 1 [5]
AB023 DMBG9HI End-stage renal disease GB61.5 Phase 1 [6]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor XI (F11) TTJCPUT FA11_HUMAN Not Available [1]

References

1 Clinical pipeline report, company report or official report of Klus Pharma
2 Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost. 2022 Jun;20(6):1400-1411.
3 Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 2022 Feb;20(2):307-315.
4 Clinical pipeline report, company report or official report of MSD
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809.